MichaÅ, Szczyrek

List of Publications by Year
in descending order

28 papers	**287** citations	840776 **11** h-index	996975 **15** g-index
28 all docs	**28** docs citations	**28** times ranked	**418** citing authors

#	Article	IF	Citations
1	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. Cells, 2022, 11, 752.	4.1	4
2	Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer. Cells, 2022, 11, 956.	4.1	4
3	The efficacy of T790M mutation testing in liquid biopsy—Real clinic data. PLoS ONE, 2022, 17, e0267846.	2.5	2
4	Effect of <i>TOP2A</i> and <i>ERCC1</i> gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients. Archives of Medical Science, 2021, 17, 474-480.	0.9	4
5	Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis. Journal of Clinical Medicine, 2021, 10, 1109.	2.4	11
6	Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Medicine, 2021, 10, 1126.	2.4	2
7	Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review. Nutrients, 2021, 13, 2217.	4.1	42
8	Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma — case series and literature review. Annals of Agricultural and Environmental Medicine, 2021, 29, 103-109.	1.0	0
9	Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy. Cancers, 2021, 13, 4806.	3.7	5
10	Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?. PLoS ONE, 2021, 16, e0257484.	2.5	8
11	Methylation of DROSHA and DICER as a Biomarker for the Detection of Lung Cancer. Cancers, 2021, 13, 6139.	3.7	7
12	Promoter polymorphisms of <i>TOP2A</i> and <i>ERCC1</i> genes as predictive factors for chemotherapy in non‐small cell lung cancer patients. Cancer Medicine, 2020, 9, 605-614.	2.8	20
13	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review. Cancers, 2020, 12, 2314.	3.7	13
14	Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. Annals of Hematology, 2020, 99, 2881-2891.	1.8	18
15	Serum brain‐derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. British Journal of Haematology, 2020, 191, 77-89.	2.5	16
16	Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients. Frontiers in Oncology, 2020, 10, 563613.	2.8	12
17	MicroRNAs aid the assessment of programmed death ligand¿½1 expression in patients with non‐small cell lung cancer. Oncology Letters, 2019, 17, 5193-5200.	1.8	14
18	Polymorphisms in the promotor region of the <i><scp>CRBN</scp></i> gene as a predictive factor for peripheral neuropathy in the course of thalidomide‐based chemotherapy in multiple myeloma patients. British Journal of Haematology, 2019, 186, 695-705.	2.5	7

#	Article	IF	Citations
19	Acute urticaria: an extremely rare adverse effect of levonorgestrel-releasing intrauterine system as a possible manifestation of progestogen hypersensitivity syndrome. Postepy Dermatologii I Alergologii, 2018, 35, 530-531.	0.9	2
20	Polymorphisms in the promoter region of the <i>CRBN</i> gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. Oncotarget, 2018, 9, 24054-24068.	1.8	6
21	The impact of intestinal microflora on the effectiveness of immunotherapy with antibodies against immune checkpoints â€" case report and literature review. Oncology in Clinical Practice, 2018, 14, 226-231.	0.1	0
22	Ivabradine attenuates the anticonvulsant potency of lamotrigine, but not that of lacosamide, pregabalin and topiramate in the tonic-clonic seizure model in mice. Epilepsy Research, 2017, 133, 67-70.	1.6	13
23	Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer. Pathology and Oncology Research, 2017, 23, 607-614.	1.9	6
24	Biomarkers of alcohol misuse: recent advances and future prospects. Przeglad Gastroenterologiczny, 2016, 2, 78-89.	0.7	30
25	The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings. Archives of Medical Science, 2016, 6, 1263-1272.	0.9	8
26	New prognostic biomarkers in multiple myeloma. Postepy Higieny I Medycyny Doswiadczalnej, 2016, 70, 811-819.	0.1	5
27	Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. Oncology Reports, 2013, 30, 1463-1472.	2.6	6
28	Chronic obstructive pulmonary disease in farmers and agricultural workers - an overview. Annals of Agricultural and Environmental Medicine, 2011, 18, 310-3.	1.0	22